|
HIV Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection.
|
31253590 |
2019 |
|
HIV-1 infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because of this, A3G-D128K expression in HIV-1 target cells is a potential anti-HIV gene therapy approach that could be combined with other therapies for the treatment and functional cure of HIV-1 infection.
|
31778955 |
2019 |
|
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
APOBEC3G (A3G) is a cellular protein that inhibits HIV-1 infection through virion incorporation.
|
31165049 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G or A3G) is a cytidine deaminase that inhibits the replication of several viruses, such as human immunodeficiency virus-1, hepatitis B virus and hepatitis C virus.
|
30862444 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Viral infectivity factor (Vif) is one of the accessory protein of human immunodeficiency virus type I (HIV-1) that inhibits host defense factor, APOBEC3G (A3G), mediated viral cDNA hypermutations.
|
31685340 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human APOBEC3G (A3G) inhibits the replication of human immunodeficiency virus-1 by deaminating cytidine at the 3'-end in the target motif 5'-CCC-3' in viral cDNA during reverse transcription.
|
31116511 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
A well-studied mechanism is APOBEC3G restriction of human immunodeficiency virus type 1, which is counteracted by a virus-encoded degradation mechanism<sup>1-4</sup>.
|
30420783 |
2019 |
|
HIV Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
The antiviral function of these proteins was first discovered when research in the field of HIV infection revealed that one member of the family, namely APOBEC3G, restricts HIV infection in T lymphocytes and that the viral infectivity factor protein drives the proteosomal degradation of this enzyme, thus overriding its antiviral function.
|
29345375 |
2018 |
|
HIV Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequency of APOBEC3G -571CC and CC + GC genotypes were higher in early HIV disease stage as compared to healthy controls (23.9% vs. 12.8%, OR = 2.23, P = 0.08; 28.3% vs. 14.1%, OR = 2.40, P = 0.04).
|
29864532 |
2018 |
|
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
The host antiviral protein APOBEC3G (A3G) antagonizes the early steps of HIV-1 infection through the combined effects of inhibiting viral cDNA production and cytidine-to-uridine-driven hypermutation of this cDNA.
|
29158605 |
2018 |
|
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Host Restriction Factors APOBEC3G/3F and Other Interferon-Related Gene Expressions Affect Early HIV-1 Infection in Northern Pig-Tailed Macaque (<i>Macaca leonina</i>).
|
30210504 |
2018 |
|
HIV-1 infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the current study was to evaluate any correlation of APOBEC3G genetic variation rs8177832 with HIV-1 infection.
|
30338740 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
|
30135687 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
APOBEC3G (A3G), an anti-human immunodeficiency virus 1 factor, deaminates cytidines.
|
28905055 |
2018 |
|
HIV-1 infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings report genetic variants possibly associated with susceptibility to HIV-1 infection (CUL5 rs11212495, rs7103534, rs7117111) and partial viral load control (APOBEC3G rs2294367).
|
28302043 |
2017 |
|
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
APOBEC3G restricts human immunodeficiency virus 1 (HIV-1) infection by creating hypermutations in proviral DNA, while HIV-1-encoded vif protein antagonizes such restriction by targeting APOBEC3G for degradation.
|
28098260 |
2017 |
|
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, latent HCMV infection downregulated the expression of HIV-1 restriction factors SAMHD1, APOBEC3G, tetherin, and Mx2 in CD34<sup>+</sup> progenitor cells, which may confer to enhanced HIV-1 infection.
|
29296946 |
2017 |
|
HIV-1 infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, a total of 483 HIV-1 seropositive men and 493 HIV-1 seronegative men were selected to investigate the association between single nucleotide polymorphisms (SNPs) of the APOBEC3G gene and susceptibility to HIV-1 infection and AIDS progression among MSM residing in northern China.
|
27730383 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
It can inhibit human immunodeficiency virus type 1 (HIV-1) replication at multiple stages and interact with apolipoprotein-B-mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G or A3G), a member of the cytidine deaminase family that exerts potent inhibitory effects against HIV-1 infection.
|
29258557 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
APOBEC3G restricts human immunodeficiency virus 1 (HIV-1) infection by creating hypermutations in proviral DNA, while HIV-1-encoded vif protein antagonizes such restriction by targeting APOBEC3G for degradation.
|
28098260 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
APOBEC3G (A3G) is a human enzyme that inhibits human immunodeficiency virus type 1 (HIV-1) infectivity, in the absence of the viral infectivity factor Vif, through deoxycytidine deamination and a deamination-independent mechanism.
|
28928403 |
2017 |
|
HIV Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Apobec3G-Based Strategies to Defeat HIV Infection.
|
26957196 |
2016 |
|
HIV-1 infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study had two main objectives: firstly, to screen a population from Burkina Faso for three variants of APOBEC3G previously described, and secondly to analyze the effect of these three variants and their haplotypes on HIV-1 infection with Circulating Recombinant Forms (CRFs) present in Burkina Faso.
|
26741797 |
2016 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.
|
26482266 |
2016 |
|
HIV-1 infection
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pokeweed antiviral protein restores levels of cellular APOBEC3G during HIV-1 infection by depurinating Vif mRNA.
|
26275799 |
2015 |